title: Relationship of Baseline Hemoglobin Level with Serum Ferritin, Postphlebotomy Hemoglobin Changes, and Phlebotomy Requirements among HFE C282Y Homozygotes.
abstract: Objectives. We aimed to examine whether baseline hemoglobin levels in C282Y-homozygous patients are related to the degree of serum ferritin (SF) elevation and whether patients with different baseline hemoglobin have different phlebotomy requirements. Methods. A total of 196 patients (124 males and 72 females) who had undergone therapeutic phlebotomy and had SF and both pre- and posttreatment hemoglobin values were included in the study. Results. Bivariate correlation analysis suggested that baseline SF explains approximately 6 to 7% of the variation in baseline hemoglobin. The results also showed that males who had higher (≥150 g/L) baseline hemoglobin levels had a significantly greater reduction in their posttreatment hemoglobin despite requiring fewer phlebotomies to achieve iron depletion than those who had lower (<150 g/L) baseline hemoglobin, regardless of whether baseline SF was below or above 1000 µg/L. There were no significant differences between hemoglobin subgroups regarding baseline and treatment characteristics, except for transferrin saturation between male subgroups with SF above 1000 µg/L. Similar differences were observed when females with higher (≥138 g/L) baseline hemoglobin were compared with those with lower (<138 g/L) baseline hemoglobin. Conclusion. Dividing C282Y-homozygous patients into just two subgroups according to the degree of baseline SF elevation may obscure important subgroup variations.
authors.affiliation: Department of Immunology and Transfusion Medicine, Akershus University Hospital, University of Oslo, Norway.
authors.forename: Seyed Ali
authors.initials: SA
authors.lastname: Mousavi
authors.affiliation: Department of Immunology and Transfusion Medicine, Akershus University Hospital, University of Oslo, Norway.
authors.forename: Faiza
authors.initials: F
authors.lastname: Mahmood
authors.affiliation: Department of Immunology and Transfusion Medicine, Akershus University Hospital, University of Oslo, Norway.
authors.forename: Astrid
authors.initials: A
authors.lastname: Aandahl
authors.affiliation: Department of Immunology and Transfusion Medicine, Akershus University Hospital, University of Oslo, Norway.
authors.forename: Teresa Risopatron
authors.initials: TR
authors.lastname: Knutsen
authors.affiliation: Department of Immunology and Transfusion Medicine, Akershus University Hospital, University of Oslo, Norway.
authors.forename: Abid Hussain
authors.initials: AH
authors.lastname: Llohn
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005293:Ferritins / Q000097:blood*; D006432:Hemochromatosis / Q000097:blood* / Q000235:genetics / Q000628:therapy*; D000071020:Hemochromatosis Protein; D006454:Hemoglobins / Q000032:analysis*; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D018962:Phlebotomy; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D006454:Hemoglobins; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D005293:Ferritins